Tags

Type your tag names separated by a space and hit enter

COVID-19 Susceptibility in Bronchial Asthma.
J Allergy Clin Immunol Pract. 2021 Feb; 9(2):684-692.e1.JA

Abstract

BACKGROUND

Bronchial asthma has not been adequately assessed in coronavirus disease 2019 (COVID-19). Respiratory allergy is associated with significant reductions in the expression of angiotensin-converting enzyme 2 receptor, which is the entry receptor for COVID-19.

OBJECTIVE

To observe COVID-19 susceptibility in patients with bronchial asthma, analyze the prevalence of asthma in a large cohort of consecutive outpatient subjects who were tested with the RT-PCR assay for COVID-19.

METHODS

This was a retrospective population-based cross-sectional study using data from a large nationwide health maintenance organization in Israel. All health maintenance organization enrollees who had been tested for COVID-19 from February to June 2020 were included. Differences in demographic and clinical characteristics between the subjects with negative and positive COVID-19 RT-PCR test results and between COVID-19 RT-PCR-positive subjects with and without asthma were analyzed.

RESULTS

A total of 37,469 subjects were tested for COVID-19 RT-PCR, and results for 2,266 (6.05%) of them were positive. A significantly higher proportion of smokers was observed in the COVID-19-negative group than in the COVID-19-positive group (4734 [13.45%] vs 103 [4.55%]; P < .001). Asthma was found in 153 (6.75 %) subjects of the COVID-19-positive group and in 3388 (9.62%) subjects of the COVID-19-negative group (P < .001). No significant impact of antileukotrienes, inhaled corticosteroids, and long-acting beta-blockers use was revealed on COVID-19 positivity proportions. Multiple logistic regression analysis adjusted for sex, age, smoking, and comorbidity revealed a negative association of asthma with the likelihood of being positive for COVID-19 (odds ratio, 0.71; 95% CI, 0.58-0.87; P = .001).

CONCLUSIONS

We observed lower COVID-19 susceptibility in patients with preexisting asthma.

Authors+Show Affiliations

Leumit Health Services, Tel-Aviv, Israel; Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.Leumit Health Services, Tel-Aviv, Israel; Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.Leumit Health Services, Tel-Aviv, Israel; Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.Leumit Health Services, Tel-Aviv, Israel; Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.Leumit Health Services, Tel-Aviv, Israel; Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben Gurion University of the Negev, Ashkelon, Israel. Electronic address: allergologycom@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

33242628

Citation

Green, Ilan, et al. "COVID-19 Susceptibility in Bronchial Asthma." The Journal of Allergy and Clinical Immunology. in Practice, vol. 9, no. 2, 2021, pp. 684-692.e1.
Green I, Merzon E, Vinker S, et al. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9(2):684-692.e1.
Green, I., Merzon, E., Vinker, S., Golan-Cohen, A., & Magen, E. (2021). COVID-19 Susceptibility in Bronchial Asthma. The Journal of Allergy and Clinical Immunology. in Practice, 9(2), 684-e1. https://doi.org/10.1016/j.jaip.2020.11.020
Green I, et al. COVID-19 Susceptibility in Bronchial Asthma. J Allergy Clin Immunol Pract. 2021;9(2):684-692.e1. PubMed PMID: 33242628.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 Susceptibility in Bronchial Asthma. AU - Green,Ilan, AU - Merzon,Eugene, AU - Vinker,Shlomo, AU - Golan-Cohen,Avivit, AU - Magen,Eli, Y1 - 2020/11/24/ PY - 2020/08/16/received PY - 2020/10/30/revised PY - 2020/11/08/accepted PY - 2020/11/27/pubmed PY - 2021/2/16/medline PY - 2020/11/26/entrez KW - Asthma KW - COVID-19 KW - Smoking KW - Susceptibility SP - 684 EP - 692.e1 JF - The journal of allergy and clinical immunology. In practice JO - J Allergy Clin Immunol Pract VL - 9 IS - 2 N2 - BACKGROUND: Bronchial asthma has not been adequately assessed in coronavirus disease 2019 (COVID-19). Respiratory allergy is associated with significant reductions in the expression of angiotensin-converting enzyme 2 receptor, which is the entry receptor for COVID-19. OBJECTIVE: To observe COVID-19 susceptibility in patients with bronchial asthma, analyze the prevalence of asthma in a large cohort of consecutive outpatient subjects who were tested with the RT-PCR assay for COVID-19. METHODS: This was a retrospective population-based cross-sectional study using data from a large nationwide health maintenance organization in Israel. All health maintenance organization enrollees who had been tested for COVID-19 from February to June 2020 were included. Differences in demographic and clinical characteristics between the subjects with negative and positive COVID-19 RT-PCR test results and between COVID-19 RT-PCR-positive subjects with and without asthma were analyzed. RESULTS: A total of 37,469 subjects were tested for COVID-19 RT-PCR, and results for 2,266 (6.05%) of them were positive. A significantly higher proportion of smokers was observed in the COVID-19-negative group than in the COVID-19-positive group (4734 [13.45%] vs 103 [4.55%]; P < .001). Asthma was found in 153 (6.75 %) subjects of the COVID-19-positive group and in 3388 (9.62%) subjects of the COVID-19-negative group (P < .001). No significant impact of antileukotrienes, inhaled corticosteroids, and long-acting beta-blockers use was revealed on COVID-19 positivity proportions. Multiple logistic regression analysis adjusted for sex, age, smoking, and comorbidity revealed a negative association of asthma with the likelihood of being positive for COVID-19 (odds ratio, 0.71; 95% CI, 0.58-0.87; P = .001). CONCLUSIONS: We observed lower COVID-19 susceptibility in patients with preexisting asthma. SN - 2213-2201 UR - https://www.unboundmedicine.com/medline/citation/33242628/COVID_19_Susceptibility_in_Bronchial_Asthma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2213-2198(20)31240-X DB - PRIME DP - Unbound Medicine ER -